Blockade of transforming growth factor‐beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line
- 14 February 2011
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 71 (13), 1441-1454
- https://doi.org/10.1002/pros.21361
Abstract
BACKGROUND The skeleton is the most common site of prostate cancer metastasis, which often results in osteoblastic lesions. The role of transforming growth factor‐beta (TGFβ) signaling in prostate cancer‐induced osteoblastic metastasis is not clear. We investigated the role of TGFβ signaling in prostate cancer‐induced bone metastasis using a novel human prostate cancer cell line, PacMetUT1. METHODS We injected PacMetUT1/Luc‐GFP cells in male nude mice by intracardiac and intratibia injections and then investigated the effect of TGFβ signaling abrogation on osteoblastic tumor growth and incidence in vivo by using fluorescence and bioluminescence imaging analysis and quantifying bone and tumor volume by histomorphometry analysis. Osteoclasts were counted using TRAP assay. RESULTS Osteoblastic bone metastasis in skull, rib, and femur was detected after 10–16 weeks of intracardiac injection of the PacMetUT1 cells. Stable knockdown of TGFβ1 with an shRNA resulted in decreased tumor incidence and bone formation when the cells were directly injected into the tibiae. Systemic administration of either a small inhibitor of TGFβ type I receptor kinase or a pan TGFβ binding protein (BGERII) also decreased bone tumor growth and osteoblastic bone formation in vivo after 7 weeks of treatment. CONCLUSIONS Our results for the first time indicate that blockade of TGFβ signaling in the PacMetUT1 model significantly inhibits osteoblastic bone formation and tumor incidence. Thus, TGFβ signaling pathway may be a viable target for the prevention and treatment of prostate cancer‐induced bone metastasis. Prostate 71:1441–1454, 2011.Keywords
Funding Information
- NIH (R01CA079683, R01CA075253, R01CA104505)
- NCI Cancer Center (P30CA054174)
This publication has 48 references indexed in Scilit:
- Pharmacologic Inhibition of the TGF-β Type I Receptor Kinase Has Anabolic and Anti-Catabolic Effects on BonePLOS ONE, 2009
- Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literatureCases Journal, 2008
- Histopathological Assessment of Prostate Cancer Bone Osteoblastic MetastasesJournal of Urology, 2008
- Expression, purification and characterization of BGERII: a novel pan-TGF inhibitorProtein Engineering, Design and Selection, 2008
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-β Type I Receptor Kinase InhibitorCancer Research, 2006
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- Role of endothelin-1 in osteoblastic bone metastasesCancer, 2003
- Aromatase in bone cell: Association with osteoporosis in postmenopausal womenThe Journal of Steroid Biochemistry and Molecular Biology, 1995